Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Meina Wu
DNA Methylation Status of WNT Antagonist SFRP5 Can Predict the Response to the EGFR-tyrosine Kinase Inhibitor Therapy in Non-Small Cell Lung Cancer
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
Optimal First‐line Treatment for Advanced Thymic Carcinoma
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
Related publications
Does the Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Differ According to the Type of EGFR Mutation in Non-Small Cell Lung Cancer?
Korean Journal of Internal Medicine
Internal Medicine
JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations
OncoTargets and Therapy
Oncology
Pharmacology
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Development and Validation of a Model to Predict Tyrosine Kinase Inhibitor-Sensitive EGFR Mutations of Non-Small Cell Lung Cancer Based on Multi-Institutional Data
Thoracic Cancer
Medicine
Pulmonary
Respiratory Medicine
Oncology
MA18.05 Characteristics and Long-Term OS of Non-Small Cell Lung Cancer Patients Receiving EGFR Tyrosine Kinase Inhibitor Treatment
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-mutated Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Non-Small Cell Lung Cancer-Small Cell Lung Cancer Transformation as Mechanism of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer
Oncology in Clinical Practice
Oncology